Vigil Neuroscience, Inc. (VIGL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, CEO & Director | 908.25k | -- | 1967 |
| Ms. Jennifer Ziolkowski CPA | Chief Financial Officer | 617.55k | -- | 1974 |
| Sharon Morani | Senior Director of Facilities & Operations | -- | -- | -- |
| Dr. David Gray Ph.D. | Chief Scientific Officer | -- | -- | 1975 |
| Ms. Leah Gibson | Vice President of Investor Relations and Corporate Communications | -- | -- | -- |
| Mr. Christopher Verni J.D. | General Counsel & Corporate Secretary | -- | -- | 1975 |
| April Effort M.B.A., M.S. | VP & Head of Corporate Development | -- | -- | -- |
| Mr. Evan A. Thackaberry DABT, Ph.D. | Senior VP & Head of Early Development | -- | -- | 1973 |
| Christian Mirescu Ph.D. | VP & Head of Neuroimmunology | -- | -- | -- |
| Weeteck Yeo Ph.D. | Senior Vice President of Strategic Operations | -- | -- | -- |
Vigil Neuroscience, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 69
Description
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Recent Events
- Apr 22, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 12, 2024PRE 14A: Proxy StatementsSee Full Filing
- Mar 26, 2024S-8: Offering RegistrationsSee Full Filing
- Jan 11, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 16, 20238-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available